|
|
|
|
LEADER |
00000nam a22000005i 4500 |
001 |
978-3-319-18518-7 |
003 |
DE-He213 |
005 |
20220111140121.0 |
007 |
cr nn 008mamaa |
008 |
150422s2015 sz | s |||| 0|eng d |
020 |
|
|
|a 9783319185187
|9 978-3-319-18518-7
|
024 |
7 |
|
|a 10.1007/978-3-319-18518-7
|2 doi
|
050 |
|
4 |
|a QR46
|
072 |
|
7 |
|a MMFM
|2 bicssc
|
072 |
|
7 |
|a MED071000
|2 bisacsh
|
072 |
|
7 |
|a MKFM
|2 thema
|
082 |
0 |
4 |
|a 616.9041
|2 23
|
245 |
1 |
4 |
|a The Future of HIV-1 Therapeutics
|h [electronic resource] :
|b Resistance Is Futile? /
|c edited by Bruce E. Torbett, David S. Goodsell, Douglas D. Richman.
|
250 |
|
|
|a 1st ed. 2015.
|
264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2015.
|
300 |
|
|
|a X, 254 p.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
490 |
1 |
|
|a Current Topics in Microbiology and Immunology,
|x 2196-9965 ;
|v 389
|
505 |
0 |
|
|a HIV Therapy Looking Towards the Future -- Computational challenges of structure-based approaches applied to HIV -- Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1 -- HIV-1 integrase multimerization as a therapeutic target -- Targeting HIV transcription: The quest for a functional cure -- Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder -- HIV-1 Gag: An Emerging Target for Antiretroviral Therapy -- The Triple Threat of HIV-1 Protease Inhibitors -- Illustrations of the HIV Life Cycle.
|
520 |
|
|
|a This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.
|
650 |
|
0 |
|a Medical microbiology.
|
650 |
|
0 |
|a Virology.
|
650 |
|
0 |
|a Diseases.
|
650 |
1 |
4 |
|a Medical Microbiology.
|
650 |
2 |
4 |
|a Virology.
|
650 |
2 |
4 |
|a Diseases.
|
700 |
1 |
|
|a Torbett, Bruce E.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
700 |
1 |
|
|a Goodsell, David S.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
700 |
1 |
|
|a Richman, Douglas D.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer Nature eBook
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319185194
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319185170
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319374505
|
830 |
|
0 |
|a Current Topics in Microbiology and Immunology,
|x 2196-9965 ;
|v 389
|
856 |
4 |
0 |
|u https://doi.uam.elogim.com/10.1007/978-3-319-18518-7
|z Texto Completo
|
912 |
|
|
|a ZDB-2-SBL
|
912 |
|
|
|a ZDB-2-SXB
|
950 |
|
|
|a Biomedical and Life Sciences (SpringerNature-11642)
|
950 |
|
|
|a Biomedical and Life Sciences (R0) (SpringerNature-43708)
|